Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)

Hong Kong · Delayed Price · Currency is HKD

165.10

+11.20 (7.28%)

Oct 14, 2026, 4:08 PM HKT

Market Cap	12.99B
Revenue (ttm)	685.64M +87.6%
Net Income	173.48M +27.9%
EPS	2.31 +14.3%
Shares Out	78.71M
PE Ratio	71.62
Forward PE	57.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,900
Open	156.00
Previous Close	153.90
Day's Range	154.30 - 166.00
52-Week Range	97.50 - 302.40
Beta	n/a
Analysts	Strong Buy
Price Target	292.71 (+77.29%)
Est. Earnings	Nov 27, 2026

About HKG:2637

Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2012

Employees 200

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2637

Full Company Profile

Financial Performance

In 2025, HKG:2637's revenue was 582.36 million, an increase of 24.79% compared to the previous year's 466.68 million. Earnings were 177.03 million, an increase of 30.09%.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 2637 stock is "Strong Buy." The 12-month stock price target is $292.71, which is an increase of 77.29% from the latest price.

Price Target

$292.71

(77.29% upside)

Analyst Consensus: Strong Buy

Stock Forecasts